Preferred Label : Vixtimotamab;
NCIt synonyms : CD33/CD3 TandAbs AMV564; CD33 x CD3 Tandem Diabody AMV-56; Anti-CD33 Antigen/CD3 Receptor Bispecific Monoclonal Antibody AMV564;
NCIt definition : An anti-CD33/anti-CD3 bispecific tetravalent antibody, with potential immunostimulatory
and antineoplastic activities. Anti-CD33/CD3 tetravalent bispecific monoclonal antibody
AMV564 possesses two antigen-recognition and binding sites, one for the CD3 complex,
a group of T-cell surface glycoproteins that complex with the T-cell receptor (TCR),
and one for CD33, a tumor-associated antigen (TAA) overexpressed on the surface of
a variety of tumor cell types. Upon infusion of vixtimotamab, this bispecific antibody
binds to CD3-expressing T-cells and CD33-expressing tumor cells, thereby crosslinking
CD33-expressing tumor cells and cytotoxic T-lymphocytes (CTLs). This may result in
a potent CTL-mediated cell lysis of CD33-expressing cells. CD33, a glycoprotein expressed
by a variety of cancers, including the majority of acute myeloid leukemias (AMLs),
and normal non-pluripotent hematopoietic stem cells, plays a key role in tumor initiation,
proliferation and progression.;
UNII : 56FUB33G5M;
CAS number : 2243775-32-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2243775-32-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : AMV 564; AMV-564; CNTO-3953; T652;
NCI Metathesaurus CUI : CL522987;
Origin ID : C135632;
UMLS CUI : C5667163;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
